Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126439091 | 12643909 | 1 | I | 20160731 | 20160811 | 20160811 | EXP | TN-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023894 | GLENMARK | M^RAD A, ESSAFI F, FOUDHAILI N, BLEL Y, THABET H, BRAHMI N, AMAMOU M.. ACUTE NIFEDIPINE POISONING: CLINICAL AND PROGNOSIS ASPECTS.. FRENCH INTENSIVE CARE SOCIETY, INTERNATIONAL CONGRESS REANIMATION. 2016;6 | 0.00 | Y | 0.00000 | 20160811 | OT | TN | TN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126439091 | 12643909 | 1 | PS | Theophylline | THEOPHYLLINE ANHYDROUS | 1 | Unknown | UNK | U | 90355 | |||||||||
| 126439091 | 12643909 | 2 | SS | NIFEDIPINE. | NIFEDIPINE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126439091 | 12643909 | 1 | Product used for unknown indication |
| 126439091 | 12643909 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126439091 | 12643909 | DE |
| 126439091 | 12643909 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126439091 | 12643909 | Shock | |
| 126439091 | 12643909 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |